{
    "2021-09-09": [
        [
            {
                "time": "2021-H1",
                "original_text": "疫苗板块2021H1总结：新冠疫苗商业化价值初现 在研管线亮点颇多",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "新冠疫苗",
                        "商业化价值",
                        "在研管线"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-01",
                "original_text": "次新宝典：本批振华新材值得追踪(2021年9月第1周)",
                "features": {
                    "keywords": [
                        "次新股",
                        "振华新材",
                        "追踪"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "新材料",
                        "制造业"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}